John Tallman

Affiliations: 
Yale University School of Medicine, New Haven, CT 
Area:
pharmacology, damage & disease
Google:
"John Tallman"
Bio:

John received his undergraduate degree and doctorate in biochemistry from Georgetown University in 1972 and rapidly gained preeminence in the field for his work on Tay-Sachs Disease in the laboratory of Roscoe O Brady at the NINCDS. Mentored in neuropharmacological research by Dr Julius Axelrod at the NIMH, Dr Tallman went on to become Chief of the Section on Biochemistry and Pharmacology in the Biological Psychiatry Branch of the NIMH. During this period, John focused his attentions on the role of neurotransmitter receptors in psychiatric disorders and treatments. In 1978, John and his longtime colleague, Dr Dorothy Gallager, elucidated the modulatory role of benzodiazepines on the GABA neurotransmitter system. Over the next 15 years, Dr Tallman continued his pioneering work investigating properties of the GABAA neurotransmitter receptor using pharmacological and molecular biological probes.

(Show more)

Mean distance: 13.8 (cluster 6)
 
SNBCP
Cross-listing: Chemistry Tree

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Albaugh PA, Marshall L, Gregory J, et al. (2002) Synthesis and biological evaluation of 7,8,9,10-tetrahydroimidazo[1,2-c]pyrido[3,4-e]pyrimdin-5(6H)-ones as functionally selective ligands of the benzodiazepine receptor site on the GABA(A) receptor. Journal of Medicinal Chemistry. 45: 5043-51
Knight AR, Stephenson FA, Tallman JF, et al. (2000) Monospecific antibodies as probes for the stoichiometry of recombinant GABA(A) receptors. Receptors & Channels. 7: 213-26
Tallman J. (2000) Dimerization of G-protein-coupled receptors: implications for drug design and signaling. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 23: S1-2
Tallman JF. (2000) Development of novel antipsychotic drugs. Brain Research. Brain Research Reviews. 31: 385-90
Tallman JF. (1999) Neuropsychopharmacology at the new millennium: new industry directions. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 20: 99-105
Tallman JF, Cassella JV, White G, et al. (1999) GABA(A) receptors: Diversity and its implications for CNS disease Neuroscientist. 5: 351-361
Knight AR, Hartnett C, Marks C, et al. (1998) Molecular size of recombinant alpha1beta1 and alpha1beta1gamma2 GABAA receptors expressed in Sf9 cells. Receptors & Channels. 6: 1-18
Tallman JF. (1998) NGD 94-1: a specific dopamine-4-receptor antagonist. Advances in Pharmacology (San Diego, Calif.). 42: 490-2
Primus RJ, Thurkauf A, Xu J, et al. (1997) II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1. The Journal of Pharmacology and Experimental Therapeutics. 282: 1020-7
Tallman JF, Primus RJ, Brodbeck R, et al. (1997) I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. The Journal of Pharmacology and Experimental Therapeutics. 282: 1011-9
See more...